Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Clinical evidence

VTS-270-001

34 evidence topics · 5 sources

Objective
Location and study date
Registry study dates
FieldRegistry record
Study start (actual)“2018-06-18”
Primary completion (actual)“2021-11-02”
Study completion (actual)“2021-11-02”
First posted“2018-08-23”
Results first posted“2024-01-17”
Study sites in the United States
FacilityLocation
“University of Arkansas System”“Little Rock, Arkansas, United States, 72205”
“Loma Linda University Health System”“Loma Linda, California, United States, 92354”
“Children's Hospital Los Angeles”“Los Angeles, California, United States, 90027”
“Children's Hospital of Orange County”“Orange, California, United States, 92868”
“Children's Hospital Colorado”“Aurora, Colorado, United States, 80045”
“Children's National Hospital”“Washington D.C., District of Columbia, United States, 20010”
“Rare Disease Research, LLC”“Atlanta, Georgia, United States, 30318”
“Rush University Medical Center”“Chicago, Illinois, United States, 60612”
“Gillette Children's Specialty Healthcare”“Saint Paul, Minnesota, United States, 55101”
“Children's Specialty Center of Nevada”“Las Vegas, Nevada, United States, 89109”
“NYU Langone Medical Center”“New York, New York, United States, 10017”
“Cincinnati Children's Hospital Medical Center”“Cincinnati, Ohio, United States, 45229”
“Oregon Health & Science University”“Portland, Oregon, United States, 97239”
“The Children's Hospital at TriStar Centennial”“Nashville, Tennessee, United States, 37203”
“Vanderbilt University Medical Center”“Nashville, Tennessee, United States, 37232”
“Dell Children's Medical Center of Central Texas”“Austin, Texas, United States, 78723”
“Carilion Medical Center, Carilion Clinic”“Roanoke, Virginia, United States, 24014”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Actual enrollment and participants analyzed by group
FieldTreatment naivePreviously treatedTotal
Overall number of baseline participants“9”“18”“27”
Description of analysis sets
Registry analysis population for baseline, outcome, and adverse event data
FieldRegistry record
Baseline, outcome, and adverse event analysis population“All enrolled participants”
Results
Participant disposition
Registry participant flow and reasons for not completing
Milestone or reasonTreatment naivePreviously treated
Started“9”“18”
Received at least 1 dose of study drug“9”“18”
Completed“1”“2”
Not completed“8”“16”
Adverse event“1”“0”
Lack of efficacy“0”“1”
Other than specified“3”“2”
Physician decision“0”“1”
Study terminated by sponsor“2”“10”
Withdrawal by subject“2”“2”
Baseline characteristics
Registry baseline demographics
CharacteristicTreatment naive (n=9)Previously treated (n=18)Total (n=27)
Age, mean (SD), years“12.33(8.718)”“17.94(13.705)”“16.07(12.388)”
Female, participants“4”“7”“11”
Male, participants“5”“11”“16”
Hispanic or Latino, participants“1”“0”“1”
White, participants“7”“17”“24”
Black or African American, participants“0”“1”“1”
Race unknown or not reported, participants“2”“0”“2”
Efficacy results
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results
Primary outcome: participants with treatment-emergent and serious adverse events
OutcomeTreatment naive (n=9)Previously treated (n=18)
All TEAEs, participants“9”“17”
SAEs, participants“5”“9”
All-cause mortality and serious adverse events by preferred term
Selected other (non-serious) adverse events reported at a 5% frequency threshold
Study limitations
Summary: design limitations of VTS-270-001
  • Control and blinding: VTS-270-001 was a non-randomized, open-label, single-arm trial with masking recorded as none; the protocol used no control product and no data monitoring committee.
  • Sample size and population: the protocol anticipated approximately 60 subjects from 30 sites, and no new subjects could enroll after 20 January 2021. The trial enrolled 27 participants (9 treatment-naïve and 18 previously treated through the expanded access program) aged 4 to 43 years. Treatment-naïve participants started at 400 mg, previously treated participants continued at their current stable dosage, and dose increases stopped as of Amendment 2 (21 April 2021).
  • Missing efficacy collection: under the amended protocol, efficacy assessments (NPC-SS and clinician CGIC) and the EQ-5D-3L were not collected or analyzed, and auditory brainstem responses were not collected as of 20 January 2021.
  • Analysis: data were summarized with descriptive statistics, with no hypothesis testing and no imputation of missing data.
  • Early termination: the trial was terminated early when the sponsor determined that the benefit-risk profile of adrabetadex was not favorable, and treatment was allowed to continue up to 20 October 2021. Of 27 participants, 1 treatment-naive and 2 previously treated participants completed; study termination by the sponsor accounted for 2 and 10 participants. After 21 June 2021, continuation required the investigator to assess that the subject was benefiting from treatment.
  • Sponsor statements: the protocol states that a comprehensive evaluation of all available clinical data “shows no clear evidence of benefit of adrabetadex in the treatment of neurologic symptoms of NPC” and that “the benefit/risk balance is negative.”